160 related articles for article (PubMed ID: 17077607)
1. [Characterization of adenovirus serotype 35 vectors using genetically modified animals and non-human primates].
Sakurai F; Kawabata K; Mizuguchi H
Yakugaku Zasshi; 2006 Nov; 126(11):1013-9. PubMed ID: 17077607
[TBL] [Abstract][Full Text] [Related]
2. [Development of a replication-incompetent adenovirus vector derived from subgroup B adenovirus serotype 35].
Sakurai F
Yakugaku Zasshi; 2008 Dec; 128(12):1751-61. PubMed ID: 19043294
[TBL] [Abstract][Full Text] [Related]
3. Development and evaluation of a novel gene delivery vehicle composed of adenovirus serotype 35.
Sakurai F
Biol Pharm Bull; 2008 Oct; 31(10):1819-25. PubMed ID: 18827334
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus serotype 35 vector-induced innate immune responses in dendritic cells derived from wild-type and human CD46-transgenic mice: Comparison with a fiber-substituted Ad vector containing fiber proteins of Ad serotype 35.
Sakurai F; Nakashima K; Yamaguchi T; Ichinose T; Kawabata K; Hayakawa T; Mizuguchi H
J Control Release; 2010 Dec; 148(2):212-8. PubMed ID: 20800630
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus vectors composed of subgroup B adenoviruses.
Sakurai F; Kawabata K; Mizuguchi H
Curr Gene Ther; 2007 Aug; 7(4):229-38. PubMed ID: 17969556
[TBL] [Abstract][Full Text] [Related]
6. Development of adenovirus serotype 35 as a gene transfer vector.
Seshidhar Reddy P; Ganesh S; Limbach MP; Brann T; Pinkstaff A; Kaloss M; Kaleko M; Connelly S
Virology; 2003 Jul; 311(2):384-93. PubMed ID: 12842627
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus serotype 35 vector-mediated transduction into human CD46-transgenic mice.
Sakurai F; Kawabata K; Koizumi N; Inoue N; Okabe M; Yamaguchi T; Hayakawa T; Mizuguchi H
Gene Ther; 2006 Jul; 13(14):1118-26. PubMed ID: 16541121
[TBL] [Abstract][Full Text] [Related]
8. Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors.
Greig JA; Buckley SM; Waddington SN; Parker AL; Bhella D; Pink R; Rahim AA; Morita T; Nicklin SA; McVey JH; Baker AH
Mol Ther; 2009 Oct; 17(10):1683-91. PubMed ID: 19603000
[TBL] [Abstract][Full Text] [Related]
9. Transduction properties of adenovirus serotype 35 vectors after intravenous administration into nonhuman primates.
Sakurai F; Nakamura S; Akitomo K; Shibata H; Terao K; Kawabata K; Hayakawa T; Mizuguchi H
Mol Ther; 2008 Apr; 16(4):726-33. PubMed ID: 18362928
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus serotype 35 vector-mediated transduction following direct administration into organs of nonhuman primates.
Sakurai F; Nakamura SI; Akitomo K; Shibata H; Terao K; Kawabata K; Hayakawa T; Mizuguchi H
Gene Ther; 2009 Feb; 16(2):297-302. PubMed ID: 18800152
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo properties of adenovirus vectors with increased affinity to CD46.
Wang H; Liu Y; Li Z; Tuve S; Stone D; Kalyushniy O; Shayakhmetov D; Verlinde CL; Stehle T; McVey J; Baker A; Peng KW; Roffler S; Lieber A
J Virol; 2008 Nov; 82(21):10567-79. PubMed ID: 18753195
[TBL] [Abstract][Full Text] [Related]
12. Pseudotyping the adenovirus serotype 5 capsid with both the fibre and penton of serotype 35 enhances vascular smooth muscle cell transduction.
Parker AL; White KM; Lavery CA; Custers J; Waddington SN; Baker AH
Gene Ther; 2013 Dec; 20(12):1158-64. PubMed ID: 24005577
[TBL] [Abstract][Full Text] [Related]
13. Transduction Properties of Adenovirus Serotype 35 Vectors After Intravenous Administration Into Nonhuman Primates.
Sakurai F; Nakamura SI; Akitomo K; Shibata H; Terao K; Kawabata K; Hayakawa T; Mizuguchi H
Mol Ther; 2008 Apr; 16(4):726-733. PubMed ID: 28178464
[TBL] [Abstract][Full Text] [Related]
14. Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector.
Sakurai F; Mizuguchi H; Hayakawa T
Gene Ther; 2003 Jun; 10(12):1041-8. PubMed ID: 12776162
[TBL] [Abstract][Full Text] [Related]
15. Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector.
Sakurai F; Mizuguchi H; Yamaguchi T; Hayakawa T
Mol Ther; 2003 Nov; 8(5):813-21. PubMed ID: 14599815
[TBL] [Abstract][Full Text] [Related]
16. Efficient gene delivery in human and rodent mast cells using adenovirus vectors.
Nakashima K; Sakurai F; Kawabata K; Mizuguchi H
J Control Release; 2008 Aug; 129(3):215-22. PubMed ID: 18572269
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of human CD46 by adenovirus serotype 35 vectors.
Sakurai F; Akitomo K; Kawabata K; Hayakawa T; Mizuguchi H
Gene Ther; 2007 Jun; 14(11):912-9. PubMed ID: 17377598
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting.
Ni S; Gaggar A; Di Paolo N; Li ZY; Liu Y; Strauss R; Sova P; Morihara J; Feng Q; Kiviat N; Touré P; Sow PS; Lieber A
Cancer Gene Ther; 2006 Dec; 13(12):1072-81. PubMed ID: 16874361
[TBL] [Abstract][Full Text] [Related]
19. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.
Barouch DH; Pau MG; Custers JH; Koudstaal W; Kostense S; Havenga MJ; Truitt DM; Sumida SM; Kishko MG; Arthur JC; Korioth-Schmitz B; Newberg MH; Gorgone DA; Lifton MA; Panicali DL; Nabel GJ; Letvin NL; Goudsmit J
J Immunol; 2004 May; 172(10):6290-7. PubMed ID: 15128818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
